Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
CTR20170119Phase 2Completed
- Sponsor
- BeiGene
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Hodgkin lymphoma (HL), sponsored by BeiGene. Started Apr 2017; status: completed.
02
Drugs
tislelizumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on CTR20170119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170119.